Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalJournal of Viral Hepatitis
Volume19 Suppl 1
Publication statusPublished - Jan 2012

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

@article{c3845a46c5144d3b8ff53791b491bb70,
title = "Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.",
author = "Massimo Colombo",
year = "2012",
month = "1",
language = "English",
volume = "19 Suppl 1",
pages = "1--2",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

AU - Colombo, Massimo

PY - 2012/1

Y1 - 2012/1

UR - http://www.scopus.com/inward/record.url?scp=84860556947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860556947&partnerID=8YFLogxK

M3 - Article

C2 - 22233406

AN - SCOPUS:84860556947

VL - 19 Suppl 1

SP - 1

EP - 2

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

ER -